A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Determine Whether, in Patients With Type 2 Diabetes at High Risk for Cardiovascular and Renal Events, Aliskiren, on Top of Conventional Treatment, Reduces Cardiovascular and Renal Morbidity and Mortality.

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Determine Whether, in Patients With Type 2 Diabetes at High Risk for Cardiovascular and Renal Events, Aliskiren, on Top of Conventional Treatment, Reduces Cardiovascular and Renal Morbidity and Mortality.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs Aliskiren (Primary)
  • Indications Diabetic angiopathies; Diabetic nephropathies; Hypertension in diabetes
  • Focus Registrational; Therapeutic Use
  • Acronyms ALTITUDE
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 15 Sep 2017 Results of a post-hoc analysis assessing Michigan Neuropathy Screening Instrument (MNSI) prognostic information concerning cardiovascular risks, presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
    • 03 Nov 2012 Second interim analysis published in the New England Journal of Medicine.
    • 03 Nov 2012 Primary endpoint 'Major-adverse-cardiac-event-rate' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top